ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

Reddy, Sreekanth P and Umesh, Srikantha and Thota, Balaram and Tandon, Ashwani and Pandey, Paritosh and Hegde, AS and Balasubramaniam, Anandh and Chandramouli, BA and Santosh, Vani and Rao, MRS and Kondaiah, Paturu and Somasundaram, Kumaravel (2008) PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value. In: Cancer Biology and Therapy, 7 (5). pp. 663-668.

Full text not available from this repository. (Request a copy)


Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n=91) and normal brain samples (n=9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.

Item Type: Journal Article
Publication: Cancer Biology and Therapy
Publisher: Landes Bioscience
Additional Information: Copyright of this article belongs to Landes Bioscience.
Department/Centre: Division of Biological Sciences > Biochemistry
Date Deposited: 04 Aug 2008
Last Modified: 27 Aug 2008 13:41
URI: http://eprints.iisc.ac.in/id/eprint/15441

Actions (login required)

View Item View Item